ClinicalTrials.gg
Active, not recruitingNCT07186413AKLIEFUpdated Aug 24, 2026

A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris

A Phase 3 interventional study of Trifarotene and Vehicle Cream in Acne Vulgaris, sponsored by Galderma R&D. Active, not recruiting at 1 site in China. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
561
Allocation
Randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.

Planned enrollment
6th of 12
561 · median 507
Started
2025
the only one that year
Phase 3
6 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
9 of 12
Galderma R&D

Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 6th largest by planned enrollment, is the only one that started in 2025, is one of 6 in phase 3, and was the 12th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About trifarotene

trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing trifarotene in Acne Vulgaris as a file.
02

Study summary

The primary objective is to assess the efficacy of trifarotene 50 microgram per gram (mcg/g) cream versus vehicle cream when applied once daily (QD) for 12 weeks in Chinese participants with moderate facial and truncal acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet the following criteria to be included in the study:

  1. Male or female Chinese participants aged 9 years or older at the screening visit.
  2. A minimum of 20 inflammatory lesions and 25 non-inflammatory lesions on the face at Screening and Baseline.
  3. Facial acne vulgaris severity grade 3 (moderate) on the IGA scale at Screening and Baseline.
  4. A minimum of 20 inflammatory lesions and 20 non-inflammatory lesions but no more than 100 non-inflammatory lesion counts on the trunk (shoulders, upper back, and upper anterior chest) reachable for self-application of product by the participant at Screening and Baseline (optional criterion for participant between 9 and 11 years of age).
  5. Acne vulgaris severity grade 3 (moderate) on the PGA scale at Screening and Baseline visits on trunk (shoulders, upper back and upper anterior chest) reachable for self-application of investigational product by the participant (optional criterion for participants between 9 and 11 years of age).
  6. Female participants of non-, i.e., premenstrual, or . Postmenopausal participants must meet one criterion at Screening:

    • Absence of menstrual bleeding for 1 year before screening with no other medical reason, confirmed with follicle-stimulating hormone level in the postmenopausal range.
    • Documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy at least 3 months before Screening.
  7. Female participants of childbearing potential (i.e., fertile, after menarche and until becoming postmenopausal unless permanently sterile) must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test (UPT) at the baseline visit (with a sensitivity of 25 international units per litre [IU/L] or less). They must use at least 1 adequate and approved method of throughout the study and for 1 month after the last dose of investigational product.
  8. Premenstrual participants who start menses during the study must use at least 1 adequate and approved method of contraception throughout the study and for 1 month after the last dose of investigational product.
  9. Willing and able to comply with all the time commitments and procedural requirements of the clinical study protocol.
  10. Understands and signs an form (ICF) at the screening visit, before any investigational procedures are performed.
  11. Participants who are younger than 18 years of age and whose parent/legal representative is willing/able to comply with the study requirements and understand/sign the ICF at the screening visit, before any investigational procedures are performed, will sign the assent ICF at the screening visit.
  12. At selected clinical sites: If a participant who is 18 years of age or older at the screening visit and agrees to participate in study photographs, verified by dating and signing a separate approved photography ICF. For participants younger than 18 years of age, an assent photography ICF signed by the participant in conjunction with a photography ICF signed by the parents(s)/legal representative at the screening visit.
  13. Participant is informed of terms pertaining to personal information protection and privacy and is willing to share personal information and data, in accordance with local regulations.

Exclusion criteria

Exclusion Criteria:

Participants meeting the following criteria at the screening or baseline visits are ineligible to participate in this study:

  1. Pregnant women (positive serum pregnancy test result at the screening visit or positive UPT at the baseline visit), breastfeeding women, or women planning a pregnancy during the study or within 1 month after the last product application.
  2. Severe forms of acne (e.g., acne conglobata, acne fulminans) or secondary acne form (e.g., chloracne, drug-induced acne) at the screening and baseline visits.
  3. More than 1 nodule on the face at the screening and baseline visits.
  4. More than 1 nodule on the trunk at the screening and baseline visits.
  5. Any acne cyst on the face at the screening and baseline visits.
  6. Any acne cyst on the trunk at the screening and baseline visits.
  7. Facial or truncal hair that may interfere with the study assessments according to investigator's judgment.
  8. Abnormal pigmentation, wound, scar, or tattoo on the face or on the shoulders, upper back, or chest that may interfere with the study assessments according to investigator's judgment.
  9. Any uncontrolled or serious disease or any medical or surgical condition that may interfere with the interpretation of the study results and/or put the participant at significant risk according to investigator's judgment.
  10. Abnormal laboratory test results at the screening visit (hematology, comprehensive metabolic panel, and urinalysis) judged as by the investigator (to be checked before the baseline visit), which may interfere with the interpretation of the study results and/or put the participant at significant risk (e.g., elevated (ALT) or aspartate aminotransferase (AST) (> 3 × [ULN])).
  11. Known allergies or to any component of the formulation of the investigational products (trifarotene 50 mcg/g cream or vehicle cream; see Investigator's Brochure).
  12. Previously participated in any trifarotene cream clinical study.
  13. Current participation in any other clinical study of a drug or device OR past participation within 30 days before the baseline visit.
  14. Alcohol or drug abuse or substance dependence within 12 months before the screening visit.
  15. Inability or unwillingness to undergo multiple venipunctures because of poor tolerability or venous access.
  16. Loss of over 500 mL of blood or blood donation within the last 3 months before the screening visit.
  17. Having received prohibited medication or treatment during the study.
  18. Exposure to excessive ultraviolet (UV) radiation within 1 month before the baseline visit.
  19. Unwillingness to avoid excessive or prolonged exposure to UV light (i.e., occupational exposure to the sun, sunbathing, tanning bed use, phototherapy) throughout the study.
  20. Any drug that in the opinion of the investigator may interfere with the study assessments or exacerbate acne, i.e., lithium, halogens, haloperidol, hydantoin, phenobarbital, Vitamin B12, androgens.
  21. Unwillingness to refrain from prohibited medication during the clinical study as defined by protocol.
  22. Participant vulnerability (such as freedom deprivation, mental disease, those incapable of giving consent) as defined in Section 1.61 of the International Council for Harmonization Guideline for Good Clinical Practice (GCP).
  23. More than 1 participant sharing the same household.
  24. Clinical site personnel, close relatives of the clinical site personnel (e.g., parents, children, siblings, or spouse), employees, or close relatives of employees of the Sponsor company.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
561 participants (estimated)

Study arms

  • Experimental
    Trifarotene Cream

    Participants will apply Trifarotene 50 mcg/g cream once daily (QD) in the evening for 12 weeks.

    Drug: Trifarotene

  • Active comparator
    Vehicle Cream

    Participants will apply Vehicle cream QD in the evening for 12 weeks.

    Drug: Vehicle Cream

Interventions

  • Trifarotene cream applied QD topically.

    Also known as: CD5789

  • DrugVehicle Cream

    Vehicle cream applied QD topically.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Investigator Global Assessment (IGA) Success (Face only) at Week 12

    The areas defined for IGA assessment are the forehead, each cheek, chin, and nose. IGA will be confined to a global assessment of each area defined above. IGA consists of 5 grades ranging from 0-4 where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. Success Rate, defined as the percentage of participants who achieve an IGA score (face only) of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.

    Time frame: Baseline to Week 12

  2. Change from Baseline to Week 12 in Facial Non-inflammatory Lesion Count

    Time frame: Baseline to Week 12

  3. Change from Baseline to Week 12 in Facial Inflammatory Lesion Count

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Percentage of Participants with Physician Global Assessment (PGA) Success at Week 12

    The areas defined for PGA assessment are shoulders, upper back and upper anterior chest which are accessible to self-application by the participants. PGA will be confined to a global assessment of each areas defined above. The PGA is a snapshot static assessment to be done prior to detailed lesion counts. PGA consists of 5 grades ranging from 0-4 where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe. PGA Success, defined as the percentage of participants who achieve a PGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12

    Time frame: Baseline to Week 12

  2. Change from Baseline to Week 12 in Truncal Non-inflammatory Lesion Count

    Time frame: Baseline to Week 12

  3. Change from Baseline to Week 12 in Truncal Inflammatory Lesion Count

    Time frame: Baseline to Week 12

  4. Number of Participants With Adverse Events (AEs), Including AEs of Special Interest (AESIs), Treatment-emergent AEs (TEAEs), and Serious AEs (SAEs)

    Time frame: Baseline to Week 12

  5. Investigator's Local Tolerability Assessment

    Local tolerability, which includes individual assessment of erythema, scaling, dryness, and stinging/burning, will be graded on a 4-point scale (ranging from 0 \[None\] to 3 \[Severe\]) separately for the face and trunk. A higher score indicated a severe outcome. The areas for evaluation on the face include the forehead, nose, chin, and right and left cheeks. The areas for evaluation on the upper trunk include the shoulders, right and left chest, and right and left upper back, which are accessible to self-application by the subject. If IP is applied to the middle and/or lower back, the local tolerability assessment of the trunk will include the upper, middle, and/or lower back, if applicable, and will be analyzed as 1 area.

    Time frame: Baseline, Weeks 1, 2, 4, 8 and 12

  6. Observed Plasma Concentration (Ct) in Selected Participants

    Three PK samples will be collected to inform trifarotene exposure in adult participants.

    Time frame: Baseline, Week 4 and Week 12

07

Study locations

1 site
  • Galderma Research & Development Site #5378
    Shanghai, Jing'an District, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's planned 15 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 22, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07186413
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Sep 23, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trifarotene

Start the discussion